Advanced Accelerator Applications (NASDAQ: AAAP) and Repligen Corporation (NASDAQ:RGEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Institutional and Insider Ownership

37.5% of Advanced Accelerator Applications shares are owned by institutional investors. Comparatively, 97.9% of Repligen Corporation shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Advanced Accelerator Applications has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Repligen Corporation has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Profitability

This table compares Advanced Accelerator Applications and Repligen Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Advanced Accelerator Applications -33.83% -16.05% -11.18%
Repligen Corporation 15.61% 9.90% 5.93%

Analyst Recommendations

This is a summary of current ratings and target prices for Advanced Accelerator Applications and Repligen Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Accelerator Applications 0 1 4 0 2.80
Repligen Corporation 0 1 3 0 2.75

Advanced Accelerator Applications presently has a consensus target price of $56.50, suggesting a potential downside of 17.75%. Repligen Corporation has a consensus target price of $46.00, suggesting a potential upside of 19.48%. Given Repligen Corporation’s higher probable upside, analysts clearly believe Repligen Corporation is more favorable than Advanced Accelerator Applications.

Valuation & Earnings

This table compares Advanced Accelerator Applications and Repligen Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Advanced Accelerator Applications $148.93 million 20.37 -$20.10 million ($0.88) -78.06
Repligen Corporation $113.32 million 12.69 $29.54 million $0.51 75.49

Repligen Corporation has higher revenue, but lower earnings than Advanced Accelerator Applications. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Summary

Repligen Corporation beats Advanced Accelerator Applications on 9 of the 13 factors compared between the two stocks.

Advanced Accelerator Applications Company Profile

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Receive News & Ratings for Advanced Accelerator Applications S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications S.A. and related companies with MarketBeat.com's FREE daily email newsletter.